survodutide mastery course
Unit 9 of 12
Dosing and Administration
clinical trial protocols, escalation schedules, and flexible dosing rules
Clinical Dosing Context
This unit documents dosing protocols from clinical trials for educational purposes. None of the information presented constitutes medical advice, and no dosing regimen has been validated for use outside of controlled clinical trial settings. Survodutide is not commercially available and all protocols described are investigational.
Interactive Dose Escalation Planner
Visualize the escalation schedules used across survodutide clinical trials.
dose escalation planner
key numbers
dosing parameters from clinical trial protocols.
0.3-6.0 mg
clinical dose range (weekly SC injection)
28 weeks
Phase 3 escalation duration (vs 12 weeks in Phase 2)
4-week
intervals between dose steps in Phase 3
~6 days
half-life enabling once-weekly dosing
Survodutide is an investigational compound with no approved dosing regimen. All protocols described here are from controlled clinical trials. This unit documents trial designs for educational purposes only and does not constitute medical advice or dosing guidance.
key terms
dosing and pharmacokinetic vocabulary for this unit. tap to expand.
S
Subcutaneous injection. The needle is inserted into the fat layer between the skin and muscle. Survodutide uses abdominal SC injection via a pre-filled pen device, similar to semaglutide and tirzepatide delivery systems.
T
Time to maximum plasma concentration. For survodutide, Tmax is approximately 24-48 hours after injection. The C18 fatty acid acylation creates a slow-release depot through albumin binding, extending absorption from the injection site.
S
The point where drug input equals elimination, producing stable plasma levels. With a ~6-day half-life and weekly dosing, survodutide reaches steady state in approximately 4-5 weeks at each dose level. This is why 4-week dose steps are used in Phase 3.
F
Phase 3 protocol innovation allowing patients to pause 1-2 doses, step down one level, or extend time at a dose if GI symptoms are intolerable. This replaced the rigid Phase 2 schedule where the only option for intolerance was discontinuation.
D
Plasma levels increase proportionally with dose. Survodutide demonstrated dose-proportional pharmacokinetics in Phase 1, meaning doubling the dose approximately doubles the exposure. This predictability simplifies dose selection.
Phase 2 vs Phase 3 escalation
the key protocol changes designed to improve retention in Phase 3.
Phase 2: rapid, fixed
12 weeks to reach 4.8 mg maximum. 2-week intervals. no pause or step-down options. discontinuation was the only escape valve for intolerance.
Phase 3: extended, flexible
28 weeks to reach 6.0 mg maximum. 4-week intervals. pause, step-down, and dietary counseling built in. target dose 25% higher than Phase 2.